Atyr Pharma Inc. (ATYR) has disclosed a new risk, in the Share Price & Shareholder Rights category.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Atyr Pharma Inc. faces a significant listing risk after receiving a Nasdaq deficiency notice on December 4, 2025, for its common stock trading below the $1.00 minimum bid price for 30 consecutive business days. Failure to regain compliance within the permitted periods, potentially via measures such as a reverse stock split, could result in delisting from The Nasdaq Capital Market.
If Atyr Pharma Inc. is ultimately delisted, its shares could migrate to over-the-counter markets, likely reducing liquidity, heightening price volatility, and impairing price discovery. Such an outcome could also restrict access to capital, diminish analyst coverage, and erode confidence among investors, partners, and employees, thereby adversely affecting its long-term prospects.
The average ATYR stock price target is $1.00, implying 21.36% upside potential.
To learn more about Atyr Pharma Inc.’s risk factors, click here.